Evidence map›Paper›PMID 32492516›Full record

ArticleOral oncology2020

Evaluation of pathologic staging using number of nodes in p16-negative head and neck cancer.

Douglas R Farquhar, Andrew J Coniglio, Maheer M Masood, Nicholas Lenze, Paul Brennan, Devasena Anantharaman, Behnoush Abedi-Ardekani, Adam M Zanation, Mark C Weissler, Andrew F Olshan and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Douglas R FarquharDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States. Electronic address: Douglas.Farquhar@unchealth.unc.edu.
Andrew J ConiglioDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
Maheer M MasoodDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States; Department of Otolaryngology/Head and Neck Surgery, University of Kansas Medical Center, Kansas City, KS, United States.
Nicholas LenzeDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
Paul BrennanInternational Agency for Research on Cancer (IARC/WHO), Genetic Epidemiology Group, Lyon, France.
Devasena AnantharamanInternational Agency for Research on Cancer (IARC/WHO), Genetic Epidemiology Group, Lyon, France.
Behnoush Abedi-ArdekaniInternational Agency for Research on Cancer (IARC/WHO), Genetic Cancer Susceptibility Group, Lyon, France.
Adam M ZanationDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
Mark C WeisslerDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
Andrew F OlshanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States; Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
Siddharth ShethDivision of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States; Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
Trevor G HackmanDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States.
University of North Carolina at Chapel Hill · USCentre international de recherche sur le cancer · FR

Funding

Gene Environment Interaction in Head and Neck CancerR01CA090731 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI OLSHAN, ANDREW · 2001 to 2005
$4.6M
Research Training in OtolaryngologyT32DC005360 · NIDCD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MANIS, PAUL B · 2003 to 2023
$2.8M
NCI NIH HHS R01 CA090731NIDCD NIH HHS T32 DC005360World Health Organization 001
6 · The paper itself

Abstract

objectivesThe 8th edition AJCC staging guidelines for head and neck squamous cell carcinoma (HNSCC) recently introduced pathologic staging criteria for nodal disease among p16-positive patients. In this study we evaluate pathologic staging in p16-negative HNSCC. MATERIALS AND

methodsWe compared pathologic staging to the 7th and 8th edition AJCC staging systems using a statewide population-based cohort. All M0 p16-negative surgical patients were included. The outcome was five-year overall survival.

resultsOf 304 patients identified, 113 were N0, 157 had 1-4 positive nodes, and 34 had ≥4 nodes. Survival was 71% (95% CI 61-78%) with no nodes, 48% (36%-60%) for 1-4 nodes, and 24% (11 - 39%) for > 4 nodes. When compared to the AJCC systems, the pathologic staging yielded a larger total survival gradient, more montonic survival, better consistency across primary sites, and a slightly lower Bayesian information criterion (1510 vs 1538). After adjusting for disease characteristics, demographics, and tobacco use, hazard ratios for survival were similar using pathologic and AJCC criteria.

conclusionIn this cohort, pathological staging was more prognostic than AJCC staging. This is the first study to evaluate pathologic staging in p16-negative cancer; if these findings are verified, a universal nodal staging system could be introduced.

Indexed as

AgedFemaleHead and Neck NeoplasmsHumansLymphatic MetastasisLymph NodesMaleMiddle AgedNeoplasm StagingAJCC StagingHead and Neck CancerHead and Neck Squamous Cell CarcinomaHPV-negativeNodal DiseaseNodal StagingP16-negativePathologic StagingSurvival

Identifiers

PMID32492516
PMCPMC7483879
OpenAlexW3029909801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.